Are you a healthcare professional?

Yes No

KUVAN Dosage Forms

For those who respond, KUVAN® (sapropterin dihydrochloride) Tablets or Powder for Oral Solution—in combination with a low-Phe diet—can help reduce blood Phe levels.1

KUVAN is offered in three different dosage forms:

  • 100 mg Tablets
  • 100 mg Powder Packets
  • 500 mg Powder Packets

Available in a convenient 500 mg packet

Kuvan_2Pkgsandbottle-straighton_small

KUVAN Powder Offers Quick and Easy Preparation

  • Just open and mix
  • Dissolves completely within 15 seconds
  • May be dissolved in water or apple juice or mixed in a small amount of soft food, such as apple sauce or pudding. Drink or eat the mixture within 30 minutes
  • Sweet taste with lower acidity compared to KUVAN Tablets
  • Preparation eases transition for those already on KUVAN Tablets
    • One packet of KUVAN Powder 100 mg equals one KUVAN Tablet
    • One KUVAN Powder 500 mg packet equals five 100 mg tablets or five 100 mg packets

A Convenient Option to Help Patients Better Manage PKU

  • For those who respond, KUVAN® (sapropterin dihydrochloride) Powder 500 mg offers improved convenience
    • Delivers the proven efficacy and established safety profile recognized throughout 8 years of approved KUVAN use1
  • Patients and caregivers will have fewer packets to open, which will make it easier to include this treatment in their daily routine
  • Because PKU requires tight daily management, a medication that is easier to dose and take could help support a successful treatment plan
    • If adherence is a challenge, KUVAN Powder 500 mg could help make a difference

d_f1

Some patients may have 2 co-pays if their prescription includes both 500 mg KUVAN Powder and 100 mg KUVAN Powder (or 100 mg KUVAN Tablets).

For eligible individuals, financial assistance may be available. Please contact BioMarin RareConnections™ for case management and reimbursement support. Learn more.

Reference

  1. KUVAN [package insert]. Novato, CA: BioMarin Pharmaceutical Inc; 2015.

INDICATION

KUVAN® (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution are indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age or older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet.

IMPORTANT SAFETY INFORMATION

Treatment with KUVAN should be directed by physicians knowledgeable in the management of PKU. Prolonged exposure to elevated blood Phe levels can result in severe neurologic damage in PKU patients.

The use of KUVAN does not eliminate the need for careful monitoring of blood Phe levels and ongoing dietary management to ensure adequate Phe control and nutritional balance. Response to KUVAN can only be determined by a therapeutic trial. Patients should be advised to notify their physicians in cases of overdose.

Warnings and Precautions

  • Hypersensitivity Reactions Including Anaphylaxis: KUVAN is not recommended in patients with a history of anaphylaxis to KUVAN. Hypersensitivity reactions, including anaphylaxis and rash, have occurred. Signs of anaphylaxis include wheezing, dyspnea, coughing, hypotension, flushing, nausea, and rash. Discontinue KUVAN treatment in patients who experience anaphylaxis, and initiate appropriate medical treatment. Continue dietary Phe restrictions in patients who experience anaphylaxis.
  • Upper Gastrointestinal Mucosal Inflammation: Gastrointestinal (GI) adverse reactions suggestive of upper GI mucosal inflammation have been reported with KUVAN. Serious adverse reactions included esophagitis and gastritis. If left untreated, these could lead to severe sequelae including esophageal stricture, esophageal ulcer, gastric ulcer, and bleeding, and such complications have been reported in patients receiving KUVAN. Monitor patients for signs and symptoms of upper GI mucosal inflammation.
  • Hypophenylalaninemia: Some patients receiving KUVAN can experience significant drops in blood Phe levels, and children younger than 7 years old treated with KUVAN doses of 20 mg/kg per day are at an increased risk for low levels of blood Phe compared with children 7 years and older.
  • Monitoring Blood Phe Levels During Treatment: Prolonged elevations of blood Phe levels in patients with PKU can result in severe neurologic damage, including severe intellectual disability, developmental delay, microcephaly, delayed speech, seizures, and behavioral abnormalities. Conversely, prolonged levels of blood Phe that are too low have been associated with catabolism and endogenous protein breakdown, which has been associated with adverse developmental outcomes. Active management of dietary Phe intake and frequent blood Phe monitoring while taking KUVAN is required to ensure adequate Phe control and nutritional balance, especially in the pediatric population.
  • Lack of Biochemical Response to KUVAN: Not all patients with PKU respond to treatment with KUVAN. Biochemical response to KUVAN treatment cannot generally be pre-determined by laboratory testing (e.g., molecular testing), and should be determined through a therapeutic trial (evaluation) of KUVAN response.
  • Interactions with Levodopa: In a post-marketing safety surveillance program for a non- PKU indication using another formulation of the same active ingredient (sapropterin), there have been reports of an interaction with levodopa causing seizures, exacerbation of seizures, over-stimulation, and irritability. Monitor patients who are receiving levodopa for a change in neurologic status during treatment with KUVAN.
  • Hyperactivity: There have been post-marketing reports of hyperactivity with administration of KUVAN. Monitor patients for hyperactivity.

Adverse Reactions

  • Most common: The most common adverse reactions (incidence ≥4%) were headache, rhinorrhea, pharyngolaryngeal pain, diarrhea, vomiting, cough, and nasal congestion.
  • Additional adverse reactions reported in connection with worldwide marketing: hypersensitivity reactions including anaphylaxis and rash, esophagitis, gastritis, oropharyngeal pain, pharyngitis, esophageal pain, abdominal pain, dyspepsia, nausea, vomiting, and hyperactivity.

Additional Drug Interactions

  • Frequently monitor blood Phe levels when co-administering KUVAN with medications known to inhibit folate metabolism, such as methotrexate, valproic acid, phenobarbital, trimethoprim.
  • Monitor patients for hypotension when co-administering KUVAN with medications known to affect nitric oxide–mediated vasorelaxation such as PDE-5 inhibitors including sildenafil, vardenafil, or tadalafil.

To report SUSPECTED ADVERSE REACTIONS, contact BioMarin Pharmaceutical Inc. at 1-866-906-6100, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please read the full Prescribing Information by clicking here.